IFP Advisors Inc Purchases 5,361 Shares of Novavax, Inc. (NASDAQ:NVAX)

IFP Advisors Inc increased its position in shares of Novavax, Inc. (NASDAQ:NVAX – Get Rating) by 328.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,994 shares of the biopharmaceutical company’s stock after buying an additional 5,361 shares during the quarter. IFP Advisors Inc’s holdings in Novavax were worth $52,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of NVAX. Neo Ivy Capital Management acquired a new stake in Novavax during the 3rd quarter worth approximately $37,000. Credit Agricole S A increased its stake in Novavax by 65.8% during the 3rd quarter. Credit Agricole S A now owns 2,520 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 1,000 shares during the period. Nisa Investment Advisors LLC increased its stake in Novavax by 3,348.3% during the 3rd quarter. Nisa Investment Advisors LLC now owns 3,000 shares of the biopharmaceutical company’s stock worth $62,000 after acquiring an additional 2,913 shares during the period. Xponance Inc. bought a new position in Novavax during the 4th quarter worth $116,000. Finally, Hennion & Walsh Asset Management Inc. increased its stake in Novavax by 14.3% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 11,783 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 1,472 shares during the period. 45.70% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on NVAX shares. StockNews.com raised Novavax from a “sell” rating to a “hold” rating in a report on Friday, May 12th. TD Cowen downgraded Novavax from an “outperform” rating to a “market perform” rating in a report on Thursday, April 20th. B. Riley downgraded Novavax from a “buy” rating to a “neutral” rating in a report on Wednesday, March 1st. Finally, HC Wainwright cut their target price on Novavax from $110.00 to $35.00 in a report on Wednesday, May 10th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $65.57.

Novavax Stock Performance

Shares of NVAX opened at $7.75 on Thursday. The stock has a 50 day moving average price of $7.54 and a two-hundred day moving average price of $11.32. The firm has a market capitalization of $668.90 million, a P/E ratio of -0.54 and a beta of 1.72. Novavax, Inc. has a 52 week low of $5.61 and a 52 week high of $76.77.

Novavax (NASDAQ:NVAX – Get Rating) last issued its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($3.41) EPS for the quarter, missing analysts’ consensus estimates of ($3.38) by ($0.03). The business had revenue of $81.00 million during the quarter, compared to analysts’ expectations of $94.52 million. The business’s quarterly revenue was down 88.5% on a year-over-year basis. During the same period in the prior year, the company earned $2.56 earnings per share. On average, equities analysts forecast that Novavax, Inc. will post -3.44 earnings per share for the current year.

Novavax Profile

(Get Rating)

Novavax, Inc Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.